Recommended Topic Related To:


"Oct. 24, 2012 -- One of the oldest and cheapest drugs around may be highly effective against colon cancer, a new study shows.

Some of the most cutting-edge cancer therapies involve targeted treatments used in patients with specific gene mut"...



Vectibix Side Effects Center

Medical Editor: John P. Cunha, DO, FACOEP

Vectibix (panitumumab) Injection is a cancer medication used to treat metastatic colorectal cancer that has progressed after treatment with other chemotherapy. Common side effects include diarrhea, nausea, vomiting, tiredness, constipation, abdominal pain, or growth of eyelashes.

The recommended dose of Vectibix is 6 mg/kg, administered as an intravenous infusion over 60 minutes, every 14 days. Doses higher than 1000 mg should be administered over 90 minutes. Vectibix may interact with other drugs. Tell your doctor all medications and supplements you use. Vectibix is not recommended for use during pregnancy. It may harm a fetus. Consult your doctor to discuss using at least 2 forms of birth control (e.g., condoms, birth control pills) while receiving this medication and for 6 months after the end of treatment. If you become pregnant or think you may be pregnant, tell your doctor. Based on information from related drugs, this medication may pass into breast milk. Breastfeeding is not recommended while using Vectibix and for 2 months after the end of treatment.

Our Vectibix (panitumumab) Injection Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

What is Patient Information in Detail?

Easy-to-read and understand detailed drug information and pill images for the patient or caregiver from Cerner Multum.

Vectibix in Detail - Patient Information: Side Effects

Some people receiving a panitumumab injection have had a reaction to the infusion (when the medicine is injected into the vein). Tell your caregiver right away if you feel dizzy, nauseated, light-headed, itchy, short of breath, or if you have a fever or chills during the injection.

Some of the side effects of panitumumab may not appear when you first start using the medication. Severe skin or eye reactions may occur up to 2 weeks after the start of your treatment. These effects may not clear up for weeks or even months after you stop receiving panitumumab.

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.

Call your doctor at once if you have any of these serious side effects:

  • fever, sore throat, and headache with a severe blistering, peeling, and red skin rash;
  • swelling of your hands or ankles;
  • acne, dryness, peeling, cracking, bleeding, oozing, pus, or any other sign of skin infection;
  • cough or wheezing, running out of breath easily;
  • white patches or sores inside your mouth or on your lips;
  • drowsiness, restless feeling, confusion, muscle stiffness, fast or uneven heart rate, chest pain;
  • redness, swelling, or irritation of your eyes or eyelids; or
  • swelling or infection around your fingernails or toenails.

Less serious side effects may include:

  • nausea, vomiting, stomach pain;
  • diarrhea or constipation; or
  • tired feeling.

This is not a complete list of side effects and others may occur. Tell your doctor about any unusual or bothersome side effect. You may report side effects to FDA at 1-800-FDA-1088.

Read the entire detailed patient monograph for Vectibix (Panitumumab Injection for Intravenous Use) »

What is Patient Information Overview?

A concise overview of the drug for the patient or caregiver from First DataBank.

Vectibix Overview - Patient Information: Side Effects

SIDE EFFECTS: See also Warning section.

Diarrhea, nausea, vomiting, tiredness, constipation, abdominal pain, or growth of eyelashes may occur. If any of these effects persist or worsen, tell your doctor or pharmacist promptly.

Remember that your doctor has prescribed this medication because he or she has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.

Tell your doctor right away if you have any serious side effects, including: swelling ankles/feet, unusual weakness, irregular heartbeat, severe muscle spasms, mouth sores, eye redness/itching/irritation, watery eyes, menstrual changes.

Rarely, panitumumab has caused very serious lung disease. Tell your doctor immediately if you develop symptoms of lung disease, including: cough, shortness of breath.

A very serious allergic reaction to this drug is rare. However, get medical help right away if you notice any symptoms of a serious allergic reaction, including: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.

This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist.

In the US -

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.

Read the entire patient information overview for Vectibix (Panitumumab Injection for Intravenous Use)»

What is Prescribing information?

The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.

Vectibix FDA Prescribing Information: Side Effects
(Adverse Reactions)


The following adverse reactions are discussed in greater detail in other sections of the label:

The most common adverse reactions of Vectibix are skin rash with variable presentations, hypomagnesemia, paronychia, fatigue, abdominal pain, nausea, and diarrhea, including diarrhea resulting in dehydration.

The most serious adverse reactions of Vectibix are pulmonary fibrosis, pulmonary embolism, severe dermatologic toxicity complicated by infectious sequelae and septic death, infusion reactions, abdominal pain, hypomagnesemia, nausea, vomiting, and constipation. Adverse reactions requiring discontinuation of Vectibix were infusion reactions, severe skin toxicity, paronychia, and pulmonary fibrosis.

Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates in the clinical trials of a drug cannot be directly compared to rates in clinical trials of another drug and may not reflect the rates observed in practice. The adverse reaction information from clinical studies does, however, provide a basis for identifying the adverse events that appear to be related to drug use and for approximating rates.

Safety data are available from 15 clinical trials in which 1467 patients received Vectibix; of these, 1293 received Vectibix monotherapy and 174 received Vectibix in combination with chemotherapy [see WARNINGS AND PRECAUTIONS].

The data described in Table 1 and in other sections below, except where noted, reflect exposure to Vectibix administered as a single agent at the recommended dose and schedule (6 mg/kg every 2 weeks) in 229 patients with mCRC enrolled in Study 1, a randomized, controlled trial. The median number of doses was five (range: one to 26 doses), and 71% of patients received eight or fewer doses. The population had a median age of 62 years (range: 27 to 82 years), 63% were male, and 99% were white with < 1% black, < 1% Hispanic, and 0% other.

Table 1: Per-Patient Incidence of Adverse Reactions Occurring in ≥ 5% of Patients with a Between-Group Difference of ≥ 5% (Study 1)

Body System Patients Treated With Vectibix Plus BSC
(n = 229)
Best Supportive Care (BSC) Alone
(n = 234)
All Grades (%) Grade 3-4 (%) All Grades (%) Grade 3-4 (%)
Body as a Whole
  Fatigue 26 4 15 3
  General Deterioration 11 8 4 3
  Abdominal Pain 25 7 17 5
  Nausea 23 1 16 < 1
  Diarrhea 21 2 11 0
  Constipation 21 3 9 1
  Vomiting 19 2 12 1
  Stomatitis 7 0 1 0
  Mucosal Inflammation 6 < 1 1 0
  Hypomagnesemia (Lab) 38 4 2 0
  Peripheral Edema 12 1 6 < 1
  Cough 14 < 1 7 0
  All Skin/Integument Toxicity 90 16 9 0
  Skin 90 14 6 0
  Erythema 65 5 1 0
  Dermatitis Acneiform 57 7 1 0
  Pruritus 57 2 2 0
  Nail 29 2 0 0
  Paronychia 25 2 0 0
  Skin Exfoliation 25 2 0 0
  Rash 22 1 1 0
  Skin Fissures 20 1 < 1 0
  Eye 15 < 1 2 0
  Acne 13 1 0 0
  Dry Skin 10 0 0 0
  Other Nail Disorder 9 0 0 0
  Hair 9 0 1 0
  Growth of Eyelashes 6 0 0 0
*Version 2.0 of the NCI-CTC was used for grading toxicities. Skin toxicity was coded based on a modification of the NCI-CTCAE, version 3.0.

Dermatologic, Mucosal, and Ocular Toxicity

In Study 1, dermatologic toxicities occurred in 90% of patients receiving Vectibix. Skin toxicity was severe (NCICTC grade 3 and higher) in 16% of patients. Ocular toxicities occurred in 15% of patients and included, but were not limited to, conjunctivitis (4%), ocular hyperemia (3%), increased lacrimation (2%), and eye/eyelid irritation (1%). Stomatitis (7%) and oral mucositis (6%) were reported. One patient experienced a NCI-CTC grade 3 event of mucosal inflammation. The incidence of paronychia was 25% and was severe in 2% of patients. Nail disorders occurred in 9% of patients [see WARNINGS AND PRECAUTIONS].

Median time to the development of dermatologic, nail, or ocular toxicity was 14 days after the first dose of Vectibix; the median time to most severe skin/ocular toxicity was 15 days after the first dose of Vectibix; and the median time to resolution after the last dose of Vectibix was 84 days. Severe toxicity necessitated dose interruption in 11% of Vectibix-treated patients [see DOSAGE AND ADMINISTRATION].

Subsequent to the development of severe dermatologic toxicities, infectious complications, including sepsis, septic death, necrotizing fasciitis, and abscesses requiring incisions and drainage were reported.

Infusion Reactions

Infusional toxicity was defined as any event within 24 hours of an infusion during the clinical study described as allergic reaction or anaphylactoid reaction, or any event occurring on the first day of dosing described as allergic reaction, anaphylactoid reaction, fever, chills, or dyspnea. Vital signs and temperature were measured within 30 minutes prior to initiation and upon completion of the Vectibix infusion. The use of premedication was not standardized in the clinical trials. Thus, the utility of premedication in preventing the first or subsequent episodes of infusional toxicity is unknown. Across several clinical trials of Vectibix monotherapy, 3% (43/1336) experienced infusion reactions of which approximately 1% (6/1336) were severe (NCI-CTC grade 3-4). In one patient, Vectibix was permanently discontinued for a serious infusion reaction [see DOSAGE AND ADMINISTRATION].


As with all therapeutic proteins, there is potential for immunogenicity. The immunogenicity of Vectibix has been evaluated using two different screening immunoassays for the detection of binding anti-panitumumab antibodies: an acid dissociation bridging enzyme-linked immunosorbent assay (ELISA) detecting high-affinity antibodies and a Biacore® biosensor immunoassay detecting both high- and low-affinity antibodies. For patients whose sera tested positive in screening immunoassays, an in vitro biological assay was performed to detect neutralizing antibodies.

As monotherapy: The incidence of binding antibodies (excluding pre-existing and transient positive patients) was 0.4% (3/717), as detected by the acid dissociation ELISA, and 3.8% (27/717) as detected by the Biacore® assay. The incidence of neutralizing antibodies (excluding pre-existing and transient positive patients) was 1% (7/717). There was no evidence of altered pharmacokinetic or safety profiles in patients who developed antibodies to Vectibix.

In combination with irinotecan- or oxaliplatin-based chemotherapy: The incidence of binding antibodies (excluding pre-existing positive patients) was 1% (11/1124) as detected by the acid dissociation ELISA and 0.8% (9/1123) as detected by the Biacore assay. The incidence of neutralizing antibodies (excluding pre-existing positive patients) was 0.2 % (2/1124). No evidence of an altered safety profile was found in patients who developed antibodies to Vectibix.

The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay.

Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors, including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to panitumumab with the incidence of antibodies to other products may be misleading.

Postmarketing Experience

The following adverse reactions have been identified during post-approval use of Vectibix. Because these reactions are reported in a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Read the entire FDA prescribing information for Vectibix (Panitumumab Injection for Intravenous Use) »


Vectibix - User Reviews

Vectibix User Reviews

Now you can gain knowledge and insight about a drug treatment with Patient Discussions.

Here is a collection of user reviews for the medication Vectibix sorted by most helpful. Patient Discussions FAQs

Report Problems to the Food and Drug Administration


You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Get the latest treatment options.

Use Pill Finder Find it Now See Interactions

Pill Identifier on RxList

  • quick, easy,
    pill identification

Find a Local Pharmacy

  • including 24 hour, pharmacies

Interaction Checker

  • Check potential drug interactions
Search the Medical Dictionary for Health Definitions & Medical Abbreviations